San Mateo, CA, United States of America

Ellen Yulin Tsai Chien

USPTO Granted Patents = 1 

Average Co-Inventor Count = 17.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2019

Loading Chart...
1 patent (USPTO):

Title: Profile of Inventor Ellen Yulin Tsai Chien: Innovations in Tyrosine Kinase Inhibition

Introduction: Ellen Yulin Tsai Chien is an innovative inventor based in San Mateo, California. He has made significant contributions to the field of pharmaceutical sciences, particularly in the area of tyrosine kinase inhibition, which has implications for cancer treatment and various other diseases.

Latest Patents: Tsai Chien holds a patent for "Inhibitors of Tyrosine Kinase 2 Mediated Signaling." This patent discloses compounds of specific formulas, including pharmaceutically acceptable salts, and outlines pharmaceutical compositions alongside methods of preparation and use. This innovation represents a key advancement in targeted therapies for diseases linked to tyrosine kinase pathways.

Career Highlights: Ellen Yulin Tsai Chien is currently employed at AbbVie Inc., a global biopharmaceutical company focused on developing advanced therapies. His expertise in pharmaceutical chemistry and drug development is instrumental in driving innovation within the company.

Collaborations: Throughout his career, Tsai Chien has worked alongside notable colleagues, including Maria A. Argiriadi and Eric C. Breinlinger. These collaborations have fostered a dynamic environment for innovation, enabling the development of cutting-edge pharmaceutical solutions.

Conclusion: Ellen Yulin Tsai Chien exemplifies the spirit of innovation in the pharmaceutical industry. Through his patent and collaborative efforts at AbbVie Inc., he continues to contribute to advancements that are likely to enhance therapeutic options for patients and improve healthcare outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…